Artificial Intelligence
Global Contract Research Outsourcing Industry
New York, March 05, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Contract Research Outsourcing Industry” – https://www.reportlinker.com/p04910444/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
– Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.
- Trends & Factors – Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.
- Mobile Access & App – Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.
- Complimentary Updates – for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.
- Bespoke Updates & Team Collaborations – Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.
- Knowledge Center – clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.
Abstract:
– CRO Market Slumps by -1.9% in 2020 Only to Emerge Stronger With Newer Dynamics in the Post COVID-19 World
– The global market for Contract Research Outsourcing is expected to slump by -1.9% in the year 2020 and thereafter recover to reach US$72.1 billion by the year 2027, trailing a post COVID-19 CAGR of 7% over the analysis period 2020 through 2027. The COVID-19 crisis has thrown various challenges for the pharmaceutical & biopharmaceutical contract research outsourcing industry, while opening new avenues for growth across different domains. Contract research organizations serving pharmaceutical and vaccine companies were coerced to discontinue several studies owing to restrictions regarding movement of goods along with face-to-face interactions. These mandates affected central laboratories, clinical trial sites and timelines for completion of sponsored studies. Stringent guidelines enforced by countries prevented face-to-face meetings with clients, which delayed resolution of technical issues. The situation prompted various organizations to resort to video conferencing along with advanced technologies for addressing these issues. On the positive side, the COVID-19 pandemic drove the adoption of e-Clinical systems and offered new opportunities for pandemic-related research. The outbreak and associated changes in strategies required companies to bring their projects online and comply with high visibility and tight timelines. Various organizations implemented e-Clinical systems to avoid face-to-face interactions, enabling providers of these solutions to reap rich dividends. While the pandemic affected existing projects, it enabled the pharmaceutical & biopharmaceutical outsourcing industry to witness notable surge in R&D demand.
– The trend prompted companies to shift their focus and fine-tune existing operations to ensure efficiency for COVID-19-related projects. In addition, the work-from-home trend and repurposing of projects enabled various players to pay more attention to strategic activities. The pandemic has brought various changes in the CRO industry by delaying clinical trials, requiring repurposing of development pipeline and prompting companies to explore new options to connect with patients. Factors like patient disinclination to travel and local restrictions made companies to delay or stop non-essential study visits. Organizations were affected by customer-related trial delays, access and limitations to specific trial sites, and disruptions in the supply chain. The shift towards COVID-19 vaccine and treatments increased the workload for CROs. Known for their high capacity and flexibility, majority of CROs effectively accommodated the volume within a short span. Contract research organizations made concerted efforts towards accommodation of new projects without compromising over existing projects for other medical conditions or indications. The pandemic is anticipated to benefit the biopharmaceutical drug development industry and strengthen drug development activity, requiring players to efficiently use digital solutions, data insights and patient engagements. Easing of restrictions and reopening of businesses are likely to bring non-COVID-19 trials on track and drive organizations to pay more attention to decentralized clinical trial solutions including digital platforms along with mobile phlebotomists and nurses. In addition, these clinical trials are expected to reduce the requirement for patients and other participants to travel, which remains a major challenge during the current scenario.
– Changes in business operations for pharmaceutical companies are prompting CROs and other participants to adjust their practices. The impact of COVID-19 on face-to-face interactions with clients is driving various companies to implement new platforms for virtual connectivity. The technology is enabling organizations with global operations to efficiently serve their customers. In addition to limiting employee travel and considering remote working, organizations are adopting wearable cameras to assist clients in virtual audits and plant visits. These virtual meetings are providing an effective alternative to traditional personal contacts, on-site visits and face-to-face interactions. In addition, organizations are working closely with procurement teams for sourcing necessary supplies to ensure operational continuity and serve clients in a better way. The COVID-19 healthcare emergency has created a pressing need for a collaborative approach among health authorities, pharmaceutical players, regulators and CROs for developing and producing safe and effective treatments. The holistic approach combining resources and the required expertise is expected to pave way for efficient distribution of the impending vaccine globally. CROs are partnering with pharmaceutical companies for targeting data integrity and patient safety, as well as with other stakeholders including regulators and sites for patient safety-related considerations. Players are also implementing sophisticated solutions for research sites and clinical studies to reduce the burden on healthcare providers, patients and investigational sites. CROs are anticipated to play a critical role during the pandemic by taking responsibility for consistent on-site support.
Select Competitors (Total 152 Featured) –
- Albany Molecular Research, Inc.
- Charles River Laboratories International, Inc.
- Covance Clinical Biotech
- ICON plc
- IQVIA Inc
- Jubilant Biosys Ltd.
- Laboratory Corporation of America® Holdings
- Olon Ricerca Bioscience
- PAREXEL International Corp.
- Pharmaceutical Product Development, LLC.
- Pharmaron
- PRA Health Sciences, Inc.
- Sygnature Discovery Limited
- Syneos Health
- SynteractHCR
- WuXi AppTec
Read the full report: https://www.reportlinker.com/p04910444/?utm_source=GNW
I. METHODOLOGY I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
COVID-19 Delivers Mixed Results for Contract Research
Outsourcing Industry II-2
Players Focus on Collaborative Approach II-3
Optimism Reigns in Latter Part of 2020 II-4
COVID-19 and Implications for Drug Development Regulations &
Processes II-4
Opportunities in COVID-19 Programs II-6
Parallel Gains for Development & Manufacturing II-7
Contract Research Outsourcing: An Introduction II-8
Key Service Markets II-9
Market Dynamics II-10
Key Therapeutic Areas of Clinical Trial Research II-12
Exhibit 1: Top 10 Therapeutic Categories by Number of R&D
Products in 2020 II-13
Cost Savings Hold Relevance II-13
Product Innovations & Enhanced Speed II-14
Access to Expertise & Sophisticated Technology II-14
Outlook II-14
Regional Market Analysis II-16
Future Model of CRO II-17
COMPETITIVE SCENARIO II-18
CRO: A Highly Fragmented Market II-18
Exhibit 2: Leading Players in the Global Contract Research
Outsourcing Market (2019): Percentage Breakdown of Revenues by
Player II-19
Partnership Models Pay Returns II-19
Strategies and Tactical Programs II-20
Large CROs Seek the Inorganic Growth Route II-21
Key Opportunities for CROs II-22
Technological Superiority: An Advantage II-23
Consolidation to Gain Pace II-23
Recent Market Activity II-24
2. FOCUS ON SELECT PLAYERS II-25
3. MARKET TRENDS & DRIVERS II-27
Uptrend in Advanced Medicine Concepts Favors Growth II-27
Drug Developers Bet on CROs to Sail through Challenging Aspects II-28
Pharmaceutical & Biopharmaceutical Firms Target Outsourcing II-28
Gene Therapy Offers Exciting Opportunities for CROs II-29
COVID-19 Creates a Pause in Gene Therapy Market Growth II-30
Gene Therapy Set to Witness Rapid Growth Post COVID-19 II-31
Exhibit 3: Global Gene Therapy Market in US$ Million for Years
2020, 2022, 2024, 2026 II-32
Increasing Significance of Biologic Drugs Supports Market Demand II-33
Exhibit 4: Global Biologic Drugs Market Size (in US$ Billion)
for the Years 2019, 2022 & 2025 II-34
COVID-19 Drives Strong Gains for Biologics Activity II-34
Opportunities Rife in Early Stage Drug Development II-34
Notable Trends in Pharma/Biopharma R&D Impacting CROs II-35
Advances in Digital/Technology and its Impact on Clinical
Development II-37
Significant Strides Taken in the Sphere of Current Clinical
Research II-37
Data Quality Oversight (DQO) Undergoes Change II-38
Pharmacovigilance Set to Grow II-38
Artificial Intelligence and Machine Learning Gain Interest II-39
Orphan Drugs to the Fore II-39
CROs Adapt New Technologies to See More Business in Future II-40
Streamlining Development of Novel Trial Designs II-41
Industry Witnesses Increased Spend on R&D Outsourcing II-41
Exhibit 5: Pharmaceutical R&D Spending Worldwide (USD Billion):
2015-2025 II-43
Exhibit 6: Percentage Breakdown of Total Number of Compounds in
Pipeline by Phase for Pre-Clinical, Phase I, Phase II and
Phase III: 2019 II-44
Focus on Enhancing Site Selection and Patient Enrollment II-44
CROs Enter into Alliances to Improve Efficiencies II-45
Adoption of Digital Technologies Gains Pace II-45
Toxicology Services Gain Notable Attention II-47
Pharma Companies Enter into Licensing Agreements with Biotech
Companies for New Drug Discovery II-47
Pharmaceutical & Biopharmaceutical Trends to Support CRO
Penetration II-48
Exhibit 7: Global Biopharma % R&D Outsourcing (2014-2022) II-49
Exhibit 8: New FDA Drug Approvals (2010-2019): Breakdown of
Number of Approvals by Type for New Molecular Entity (NME) and
Biologic License Application (BLA) Approvals II-50
eClinical Solutions Gain Traction II-50
Other Noteworthy Market Trends II-51
Challenges Faced by Contract Research Organizations II-52
Surging Global Population Offers Increased Growth Opportunities II-53
Exhibit 9: World Population (in Thousands) by Geographic Region
for the Years 2018, 2025, 2040, 2050 II-54
Aging Population & Increasing Burden of Chronic Diseases Spurs
Pharma Product Sales, Driving Market Growth II-54
Exhibit 10: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050 II-56
Exhibit 11: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-57
Exhibit 12: Global Annual Medical Cost of CVD in US$ Billion
(2010-2030) II-58
Exhibit 13: Fatalities by Heart Conditions: Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others II-59
Exhibit 14: World Diabetes and Population Statistics (2019,
2030 & 2045) II-60
Increasing Healthcare Expenditure and Demand for Generics to
Drive Growth II-60
Exhibit 15: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-61
Exhibit 16: Healthcare Costs as a % of GDP by Country for the
Years 2020 & 2023 II-62
4. GLOBAL MARKET PERSPECTIVE II-63
Table 1: World Current & Future Analysis for Contract Research
Outsourcing by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-63
Table 2: World Historic Review for Contract Research
Outsourcing by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 II-64
Table 3: World 15-Year Perspective for Contract Research
Outsourcing by Geographic Region – Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets for Years
2012, 2020 & 2027 II-65
Table 4: World Current & Future Analysis for Clinical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-66
Table 5: World Historic Review for Clinical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 II-67
Table 6: World 15-Year Perspective for Clinical by Geographic
Region – Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America and
Rest of World for Years 2012, 2020 & 2027 II-68
Table 7: World Current & Future Analysis for Discovery by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-69
Table 8: World Historic Review for Discovery by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 II-70
Table 9: World 15-Year Perspective for Discovery by Geographic
Region – Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America and
Rest of World for Years 2012, 2020 & 2027 II-71
Table 10: World Current & Future Analysis for Pre-Clinical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-72
Table 11: World Historic Review for Pre-Clinical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 II-73
Table 12: World 15-Year Perspective for Pre-Clinical by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027 II-74
Table 13: World Current & Future Analysis for Laboratory
Services by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-75
Table 14: World Historic Review for Laboratory Services by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 II-76
Table 15: World 15-Year Perspective for Laboratory Services by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027 II-77
Table 16: World Current & Future Analysis for Pharmaceutical &
Biopharmaceutical Companies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America and Rest of
World Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2020 through 2027 II-78
Table 17: World Historic Review for Pharmaceutical &
Biopharmaceutical Companies by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America and Rest of
World Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 II-79
Table 18: World 15-Year Perspective for Pharmaceutical &
Biopharmaceutical Companies by Geographic Region – Percentage
Breakdown of Value Revenues for USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World for Years
2012, 2020 & 2027 II-80
Table 19: World Current & Future Analysis for Medical Device
Companies by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-81
Table 20: World Historic Review for Medical Device Companies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 II-82
Table 21: World 15-Year Perspective for Medical Device
Companies by Geographic Region – Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America and Rest of World for Years 2012, 2020 & 2027 II-83
Table 22: World Current & Future Analysis for Academic
Institutes by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 II-84
Table 23: World Historic Review for Academic Institutes by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 II-85
Table 24: World 15-Year Perspective for Academic Institutes by
Geographic Region – Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027 II-86
III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1
Market Overview III-1
COVID-19 Pandemic: Mixed Bag of Opportunities for CROs III-1
Drug Developers Rely on CROs to Improve Trial Efficiency and
Cost Savings III-2
Trial Services Witness Strong Demand III-3
High Demand for Data Management Services III-3
Risk-based Monitoring Catches Pace III-3
Market Analytics III-5
Table 25: USA Current & Future Analysis for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services – Independent Analysis of Annual
Revenues in US$ Million for the Years 2020 through 2027 III-5
Table 26: USA Historic Review for Contract Research Outsourcing
by Service Type – Clinical, Discovery, Pre-Clinical and
Laboratory Services Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2012 through 2019 III-6
Table 27: USA 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-7
Table 28: USA Current & Future Analysis for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 III-8
Table 29: USA Historic Review for Contract Research Outsourcing
by End-Use – Pharmaceutical & Biopharmaceutical Companies,
Medical Device Companies and Academic Institutes Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2012 through 2019 III-9
Table 30: USA 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-10
CANADA III-11
Table 31: Canada Current & Future Analysis for Contract
Research Outsourcing by Service Type – Clinical, Discovery,
Pre-Clinical and Laboratory Services – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027 III-11
Table 32: Canada Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-12
Table 33: Canada 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-13
Table 34: Canada Current & Future Analysis for Contract
Research Outsourcing by End-Use – Pharmaceutical &
Biopharmaceutical Companies, Medical Device Companies and
Academic Institutes – Independent Analysis of Annual Revenues
in US$ Million for the Years 2020 through 2027 III-14
Table 35: Canada Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-15
Table 36: Canada 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-16
JAPAN III-17
Table 37: Japan Current & Future Analysis for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services – Independent Analysis of Annual
Revenues in US$ Million for the Years 2020 through 2027 III-17
Table 38: Japan Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-18
Table 39: Japan 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-19
Table 40: Japan Current & Future Analysis for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 III-20
Table 41: Japan Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-21
Table 42: Japan 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-22
CHINA III-23
Market Overview III-23
Market Analytics III-24
Table 43: China Current & Future Analysis for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services – Independent Analysis of Annual
Revenues in US$ Million for the Years 2020 through 2027 III-24
Table 44: China Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-25
Table 45: China 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-26
Table 46: China Current & Future Analysis for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 III-27
Table 47: China Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-28
Table 48: China 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-29
EUROPE III-30
Market Overview III-30
Amid Pandemic, CRO Industry in Europe Gears Up for Broad-based
Amendments III-30
Providers Expand Services in Downstream Drug Development III-30
Market Analytics III-32
Table 49: Europe Current & Future Analysis for Contract
Research Outsourcing by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Revenues in US$ Million for
Years 2020 through 2027 III-32
Table 50: Europe Historic Review for Contract Research
Outsourcing by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Revenues in US$ Million for Years 2012 through 2019 III-33
Table 51: Europe 15-Year Perspective for Contract Research
Outsourcing by Geographic Region – Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets for Years 2012, 2020 & 2027 III-34
Table 52: Europe Current & Future Analysis for Contract
Research Outsourcing by Service Type – Clinical, Discovery,
Pre-Clinical and Laboratory Services – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027 III-35
Table 53: Europe Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-36
Table 54: Europe 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-37
Table 55: Europe Current & Future Analysis for Contract
Research Outsourcing by End-Use – Pharmaceutical &
Biopharmaceutical Companies, Medical Device Companies and
Academic Institutes – Independent Analysis of Annual Revenues
in US$ Million for the Years 2020 through 2027 III-38
Table 56: Europe Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-39
Table 57: Europe 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-40
FRANCE III-41
Table 58: France Current & Future Analysis for Contract
Research Outsourcing by Service Type – Clinical, Discovery,
Pre-Clinical and Laboratory Services – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027 III-41
Table 59: France Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-42
Table 60: France 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-43
Table 61: France Current & Future Analysis for Contract
Research Outsourcing by End-Use – Pharmaceutical &
Biopharmaceutical Companies, Medical Device Companies and
Academic Institutes – Independent Analysis of Annual Revenues
in US$ Million for the Years 2020 through 2027 III-44
Table 62: France Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-45
Table 63: France 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-46
GERMANY III-47
Table 64: Germany Current & Future Analysis for Contract
Research Outsourcing by Service Type – Clinical, Discovery,
Pre-Clinical and Laboratory Services – Independent Analysis of
Annual Revenues in US$ Million for the Years 2020 through 2027 III-47
Table 65: Germany Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-48
Table 66: Germany 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-49
Table 67: Germany Current & Future Analysis for Contract
Research Outsourcing by End-Use – Pharmaceutical &
Biopharmaceutical Companies, Medical Device Companies and
Academic Institutes – Independent Analysis of Annual Revenues
in US$ Million for the Years 2020 through 2027 III-50
Table 68: Germany Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-51
Table 69: Germany 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-52
ITALY III-53
Table 70: Italy Current & Future Analysis for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services – Independent Analysis of Annual
Revenues in US$ Million for the Years 2020 through 2027 III-53
Table 71: Italy Historic Review for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services Markets – Independent Analysis of
Annual Revenues in US$ Million for Years 2012 through 2019 III-54
Table 72: Italy 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-55
Table 73: Italy Current & Future Analysis for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes –
Independent Analysis of Annual Revenues in US$ Million for the
Years 2020 through 2027 III-56
Table 74: Italy Historic Review for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Companies, Medical Device Companies and Academic Institutes
Markets – Independent Analysis of Annual Revenues in US$
Million for Years 2012 through 2019 III-57
Table 75: Italy 15-Year Perspective for Contract Research
Outsourcing by End-Use – Percentage Breakdown of Value Revenues
for Pharmaceutical & Biopharmaceutical Companies, Medical
Device Companies and Academic Institutes for the Years 2012,
2020 & 2027 III-58
UNITED KINGDOM III-59
Table 76: UK Current & Future Analysis for Contract Research
Outsourcing by Service Type – Clinical, Discovery, Pre-Clinical
and Laboratory Services – Independent Analysis of Annual
Revenues in US$ Million for the Years 2020 through 2027 III-59
Table 77: UK Historic Review for Contract Research Outsourcing
by Service Type – Clinical, Discovery, Pre-Clinical and
Laboratory Services Markets – Independent Analysis of Annual
Revenues in US$ Million for Years 2012 through 2019 III-60
Table 78: UK 15-Year Perspective for Contract Research
Outsourcing by Service Type – Percentage Breakdown of Value
Revenues for Clinical, Discovery, Pre-Clinical and Laboratory
Services for the Years 2012, 2020 & 2027 III-61
Table 79: UK Current & Future Analysis for Contract Research
Outsourcing by End-Use – Pharmaceutical & Biopharmaceutical
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p04910444/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Artificial Intelligence
Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third
PHILADELPHIA, May 8, 2024 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship eCOA solution, TrialMax®. By leveraging process and technology enhancements, Signant’s operational teams can reduce the time it takes to go live with electronic patient-reported outcomes solutions by thirty percent or more.
Sponsors and Contract Research Organizations (CROs) have relied on Signant’s eCOA solution for over 20 years. The solution is known for its flexibility, reliability, scientific support, global logistics support, and ability to scale to any size trial, anywhere in the world. Traditionally, the time to bring the system live for patients and sites was commensurate with the operational complexity and trial design.
According to the company, customers can now benefit from this highly customizable eCOA solution along with Signant’s leading levels of science, scale, and service – delivered under much faster timelines.
“We are excited to offer customers the best of both worlds,” said Sanjiv Waghmare, Signant’s chief product officer. “They can get the fully featured, market-leading eCOA solution they already use and love, at a much faster pace. We believe this is especially meaningful as trial designs continue to increase in complexity. We want to ensure our customers hit their FPFV dates and start collecting high quality data without worrying about if their eCOA solution will be available.”
According to Waghmare, Signant’s engineering and operational teams identified areas where process enhancements and automation could dramatically reduce common implementation steps regardless of trial complexity. These steps cover all aspects of a typical eCOA timeline including study build, testing, translations, scale management, and validation.
“This is just the beginning of our efforts to deliver complexity at speed, with outstanding quality,” continued Waghmare. “We are also bringing additional efficiencies to our processes that will accelerate post-implementation support, including reporting, analytics, and data change management.”
Signant also offers a tenured solution for eCOA studies as part of its Signant SmartSignals® Unified Platform, which is fully integrated with EDC, RTSM, eConsent, and telemedicine. For more information about all Signant’s eClinical solutions, go to www.signanthealth.com.
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Contact:
Heather [email protected]+1 610.400.4141
Logo – https://mma.prnewswire.com/media/1202052/Signant_Health_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/signant-health-extends-ecoa-leadership-position-through-operational-innovations-that-reduce-timelines-by-at-least-one-third-302138773.html
Artificial Intelligence
Ness Digital Engineering Acquires Intricity – a New York based company specializing in data strategy, governance, modernization, and monetization
NEW YORK, May 8, 2024 /PRNewswire/ — Ness Digital Engineering (Ness), a global full-lifecycle digital services transformation company, has acquired Intricity, a leading provider of data strategy, governance, modernization, and monetization solutions. The acquisition deepens Ness’s data offerings, which global F1000 clients have utilized to create new revenue streams and improve operating efficiencies.
“Ness has always had a strong capability in data engineering, and the acquisition of Intricity brings the data strategy and advisory capability. Furthermore, Ness will build on Intricity’s strategic alliances with Snowflake and Databricks,” said Ranjit Tinaikar, CEO, Ness Digital Engineering. “We are excited to welcome Intricity’s talented team to Ness, combining our strengths to deliver even greater value to our clients.”
Intricity brings deep expertise in handling complex data modernization and monetization problems that are the heart of any digital transformation today.
“Joining Ness, backed by KKR, presents an exciting opportunity to accelerate our growth trajectory worldwide. We are excited to leverage Ness’s global presence, digital competencies, and deep industry expertise to deliver digital transformation solutions to a wider range of clients,” said Arkady Kleyner, Principal & Co-Founder, Intricity. “Together, we are well-positioned to drive meaningful business outcomes and accelerate innovation for our clients.”
Commenting on the acquisition, Troy Clemente, Principal & Co-Founder, Intricity, added, “We have successfully established ourselves as experts covering the entire information lifecycle, and by joining Ness, we can accelerate our combined clients’ AI journeys based on modern data infrastructures.”
Zinnov acted as financial advisor to Ness Digital Engineering.
For more information:Tanaya Misra, Global Head – PR & [email protected]
About Ness Digital Engineering
Ness Digital Engineering, which funds managed by global investment firm KKR acquired in 2022, is a full-lifecycle digital engineering firm offering digital advisory through scaled engineering services. Headquartered in New York, Ness serves our customers across 11 innovation hubs in the US, Eastern Europe, and India. Combining our core competence in engineering with the latest in digital strategy and technology, we seamlessly manage Digital Transformation journeys from strategy through execution to help businesses thrive in the digital economy. For more information, visit www.ness.com.
Logo: https://mma.prnewswire.com/media/2144213/4406841/Ness_Blue_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ness-digital-engineering-acquires-intricity—a-new-york-based-company-specializing-in-data-strategy-governance-modernization-and-monetization-302139799.html
Artificial Intelligence
Körber Pharma and Siemens Take the Lead in ABI Research’s MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
LONDON, May 8, 2024 /PRNewswire/ — The new Competitive Assessment by global technology intelligence firm ABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & gene manufacturing. The companies evaluated and ranked are:
Market Leaders: Körber Pharma, Siemens, Apprentice, Rockwell Automation, and TulipMainstream: Dassault Systèmes, GE Digital, Honeywell, Emerson, MPDV, MasterControl, ParsecFollowers: Sepasoft
“Overall, the MES software market for pharmaceutical, biotechnology, and cell & gene manufacturing is highly competitive, and the top innovators offer very comparable solutions. Technology vendors are aggressively developing new functionality, and competitors must closely watch and identify areas where they can match or leapfrog software capabilities,” explains James Prestwood, Industrial & Manufacturing Industry Analyst at ABI Research.
A total of ten overarching criteria were chosen for the purposes of this analysis and segmented across innovation and implementation clusters. These include how comprehensive the solution is and what innovative functionality it offers, data visibility, accessibility, and security within the platform, the user experience, and the capacity of worker augmentation, the MES’s contribution to manufacturers digital thread capabilities, and the alignment of the MES software with the pharmaceutical, biotechnology, and cell & gene manufacturing markets. In addition, the report evaluates MES vendor’s ability to deliver rapid time to value, their experience in delivering the software to manufacturers, the extensiveness of the vendor’s partnership base, the support for SME manufacturers, and the comprehensiveness of the software’s pricing options.
Körber Pharma and Siemens came out on top in the competitor ranking, with both firms scoring well across all criteria. Apprentice ranked as the top innovator in the assessment, offering a wide range of strong functionality designed specifically for life sciences manufacturing, an excellent cloud-native design, and comprehensive low/no-code capabilities. Dassault Systèmes scored particularly well in the implementation criteria, ranking second, with its center-of-excellence deployment model allowing manufacturers to quickly and consistently deploy and scale DELMIA Apriso.
“Pharmaceutical, biotech, and cell & gene manufacturing have been slow to embrace digital transformation but are now catching up. The industry’s strict regulations mean new solutions must be proven, and a premium should be placed on extensive deployment experiences when choosing solutions and technology partners,” Prestwood concludes.
These findings are from ABI Research’s MES Software for Pharmaceutical, Biotech, and Cell & Gene Therapy Manufacturing Competitive Ranking report. This report is part of the company’s Industrial and Manufacturing Markets research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Competitive Ranking reports offer comprehensive analysis of implementation and innovation strategies to offer unparalleled insight into a company’s performance and standing compared to its competitors.
About ABI Research
ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.
ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info:
GlobalDeborah Petrara Tel: +1.516.624.2558 [email protected]
Logo – https://mma.prnewswire.com/media/2309035/4693374/ABI_Research_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/korber-pharma-and-siemens-take-the-lead-in-abi-researchs-mes-software-for-pharmaceutical-biotechnology-and-cell–gene-manufacturing-competitive-ranking-302139303.html
-
Artificial Intelligence5 days ago
CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized6 days ago
Improving the Developer Journey in Crafting Artificial Intelligence Applications
-
Uncategorized6 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence5 days ago
5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence5 days ago
Bitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence5 days ago
Innodisk Introduces iCAP Air: Advancing Air Quality Management through Autonomous Decision-Making
-
Artificial Intelligence6 days ago
Virtual Assistant Market Size to Grow USD 8613.5 Million by 2030 at a CAGR of 22.3% | Valuates Reports
-
Artificial Intelligence5 days ago
Appian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report